Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751398 | 0.91 | LTB4R (0.34) | LTB4R | |
| SCHEMBL25760192 | 0.90 | LTB4R (0.35) | LTB4RCCR2 | |
| SCHEMBL21751328 | 0.90 | LTB4R (0.36) | LTB4RCDC7PARP1CCR2 | |
| SCHEMBL25760181 | 0.86 | LTB4R (0.32) | LTB4R | |
| SCHEMBL21751409 | 0.86 | ADORA2B (0.34) | LTB4R | |
| SCHEMBL21751307 | 0.85 | LTB4R (0.31) | LTB4R | |
| SCHEMBL25760462 | 0.81 | ALPL (0.36) | LTB4R | |
| SCHEMBL30110621 | 0.81 | LTB4R (0.37) | LTB4R | |
| SCHEMBL20543640 | 0.81 | LTB4R (0.37) | LTB4R | |
| SCHEMBL27213525 | 0.81 | ALPL (0.35) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | LTB4R 3143/4885CDC7 1299/4885PARP1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.